GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Net Current Asset Value

GenMark Diagnostics (GenMark Diagnostics) Net Current Asset Value : $0.61 (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

GenMark Diagnostics's net current asset value per share for the quarter that ended in Dec. 2020 was $0.61.

The historical rank and industry rank for GenMark Diagnostics's Net Current Asset Value or its related term are showing as below:

GNMK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 23.88   Med: 27.63   Max: 39.41
Current: 39.41

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of GenMark Diagnostics was 39.41. The lowest was 23.88. And the median was 27.63.

GNMK's Price-to-Net-Current-Asset-Value is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 4.88 vs GNMK: 39.41

GenMark Diagnostics Net Current Asset Value Historical Data

The historical data trend for GenMark Diagnostics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Net Current Asset Value Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.81 0.16 -0.26 0.61

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.23 0.89 0.78 0.61

Competitive Comparison of GenMark Diagnostics's Net Current Asset Value

For the Medical Devices subindustry, GenMark Diagnostics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GenMark Diagnostics's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GenMark Diagnostics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where GenMark Diagnostics's Price-to-Net-Current-Asset-Value falls into.



GenMark Diagnostics Net Current Asset Value Calculation

GenMark Diagnostics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2020 is calculated as

Net Current Asset Value Per Share(A: Dec. 2020 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(172.962-129.336-0-0)/71.96
=0.61

GenMark Diagnostics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2020 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2020 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(172.962-129.336-0-0)/71.96
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GenMark Diagnostics  (NAS:GNMK) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


GenMark Diagnostics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008